Why the study?
Does intrarenal infusion of SA-446 affect systemic arterial pressure, renal function, and renin release in anesthetized dogs?
Does intrarenal infusion of SA-446 affect systemic arterial pressure, renal function, and renin release in anesthetized dogs?
The ACE inhibitor SA-446 increases renal blood flow and urine flow, and its blood pressure-lowering effect is potentiated by probenecid.
Answers are grounded in this paper and cite their sources.
SA-446 exhibits dose-dependent renal and hypotensive effects in dogs potentiated by probenecid; leaves open translation to human ACE inhibitor therapy.
The effects of an orally active inhibitor of angiotensin-converting enzyme (SA-446) on systemic arterial pressure, renal function and renin release were examined in anesthetized dogs. Intrarenal infusion of the larger dose of SA-446 (0.1 mg/min) caused an increase in RBF, urine flow and renin release and caused a fall in blood pressure. The smaller dose of SA-446 (0.02 mg/min) did not affect the blood pressure, but it increased the urine flow. However, the same dose of SA-446 in combination with probenecid caused a significant fall in blood pressure. The potentiation of SA-446 with probenecid may be explained by the elevation in plasma SA-446 concentration via the inhibition of its tubular secretion by probenecid.
No takes yet. Share an insight, caveat, or question.
Takada et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: